Stromal fap is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation

HIGHLIGHTS

• who: Pablo Moreno-Ruiz from the Karolinska Institutet, Center Karolinska, Department of Oncology-Pathology, Stockholm, Sweden Uppsala University, Genetics and Pathology, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala, Sweden University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, Groningen, The Netherlands have published the paper: Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation, in the Journal: (JOURNAL)
• what: The authors subjected a clinically well-annotated NSCLC collection to analyses of the fibroblasts' composition using as markers PDGF . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.